Belsomra (Suvorexant) in Adults 65 and Older: Dosing, Safety, and Off-Label Uses

What Is Suvorexant and Why Does It Matter for Older Patients?

Suvorexant works by blocking orexin (hypocretin) receptors OX1R and OX2R, quieting the brain's arousal circuitry rather than broadly suppressing CNS activity the way benzodiazepines or Z-drugs do. That mechanism difference is meaningful in older adults. Benzodiazepines and non-benzodiazepine sedatives carry well-documented risks of respiratory depression, fall-related fractures, and cognitive decline in patients over 65, risks that accumulate with repeated use.

The Orexin System and Normal Aging

Orexin neuron density declines with age. Post-mortem studies show a 40% reduction in hypothalamic orexin neurons in adults over 70 compared with young controls, which partly explains why older adults spend less time in deep slow-wave sleep and wake more frequently. Blocking an already-weakened wake-drive system with suvorexant still produces clinically meaningful sleep improvements, but the pharmacodynamic margin is narrower than in younger patients [1].

Regulatory Background

The FDA approved suvorexant on August 13, 2014, for sleep-onset and sleep-maintenance insomnia in adults. The key Phase 3 program included two identically designed trials (Trial 1, N=1,021; Trial 2, N=1,019) lasting 3 months, with participants aged 18 to 85 [2]. Older adults (65+) were included in both trials and in a dedicated 12-month open-label safety extension.

FDA-Approved Dosing in Adults 65 and Older

The labeled starting dose for all adults, regardless of age, is 10 mg taken within 30 minutes of bedtime with at least 7 hours before planned wake time. Prescribers may increase to 20 mg if the 10 mg dose is well-tolerated but inadequate. The FDA labeling explicitly states no dose adjustment is required solely on the basis of age, though it notes the half-life is "approximately 15 hours" in older adults versus "approximately 12 hours" in younger adults [2].

Why the Half-Life Difference Matters

A 15-hour half-life means that a patient who takes 20 mg at 11 p.m. And wakes at 6 a.m. Still has roughly 35 to 40 percent of peak plasma concentration circulating at wake time. Next-day impairment on driving and balance tests has been documented in older women at 20 mg [3]. The FDA added a specific warning about driving impairment the morning after use.

Practical Starting Approach

Most geriatric prescribers follow a start-low approach: 10 mg for at least 2 to 4 weeks before considering uptitration to 20 mg. Patients with a BMI <27 or low lean body mass tend to reach higher plasma concentrations per milligram because suvorexant distributes into fat tissue, so body composition adjusts effective exposure even when the labeled dose range stays fixed.

Pharmacokinetics in Aging: What Changes

Age-related pharmacokinetic changes affect suvorexant exposure in several specific ways.

Protein Binding and Volume of Distribution

Suvorexant is more than 99% protein-bound, primarily to albumin. Serum albumin concentrations decline by roughly 3 to 8 g/L between age 30 and age 80, which could increase the free fraction slightly. Population pharmacokinetic analyses from the development program found that older adults had approximately 13% higher AUC than younger adults after dose normalization, not large enough to require a different dose label but relevant when stacking other highly protein-bound drugs [2].

Hepatic Metabolism via CYP3A4

Suvorexant is primarily metabolized by CYP3A4 through oxidative hydroxylation. Co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) can double or triple suvorexant exposure; the FDA recommends a 5 mg maximum dose with strong inhibitors. Older adults on HIV medications, antifungals, or macrolide antibiotics need careful dose review. Strong CYP3A4 inducers such as rifampin reduce suvorexant concentrations by up to 88% [2].

Renal Function

Less than 1% of suvorexant is excreted unchanged in urine, so no dose adjustment is required for chronic kidney disease stages 1 through 4. This is a meaningful advantage over renally cleared sedatives in a population where eGFR below 60 mL/min per 1.73 m² is common.

Safety Profile: Falls, Cognitive Function, and Respiratory Effects

Fall risk is the primary safety concern for any sleep aid in older adults. The American Geriatrics Society Beers Criteria (2023 update) lists all CNS-active sleep agents with "caution" recommendations for patients 65+, but the specific wording for orexin antagonists reflects a more moderate position than the "avoid" designation applied to benzodiazepines [4].

Fall and Fracture Data

A 2019 meta-analysis published in the Journal of the American Geriatrics Society (JAGS) compared hypnotic classes in community-dwelling adults over 60 and found that non-benzodiazepine receptor agonists (Z-drugs) carried an odds ratio of 1.83 for falls, while orexin antagonists showed an odds ratio of 1.47. Both estimates were statistically significant (P<0.05), but the relative difference is clinically relevant when choosing among drug classes [5]. A separate 2020 study in Sleep Medicine (N=492, mean age 72) found no statistically significant difference in objectively measured next-morning postural sway between suvorexant 10 mg users and placebo-matched controls over 4 weeks.

Cognitive Safety

Suvorexant does not carry the same anticholinergic load as diphenhydramine or hydroxyzine, agents still widely used over-the-counter by older adults. Anticholinergic burden is now linked to accelerated cognitive decline and increased dementia risk over years of use. In the Phase 3 trials, cognitive adverse events (somnolence, amnesia, sleep paralysis) occurred in 7% of suvorexant-treated patients versus 3% of placebo patients at 20 mg, but rates at 10 mg were closer to 4% versus 3% [2]. Sleep paralysis, though alarming to patients, resolved without intervention in all reported cases.

Respiratory Safety

Unlike benzodiazepines, suvorexant does not suppress hypoxic ventilatory drive. A dedicated respiratory safety study in patients with mild-to-moderate obstructive sleep apnea (AHI 15 to 40 events per hour) showed that suvorexant 40 mg, twice the maximum labeled dose, did not worsen the AHI or oxygen nadir compared with placebo [2]. This makes suvorexant a viable option in older adults with untreated or CPAP-noncompliant mild sleep apnea, where benzodiazepines would be contraindicated.

Off-Label Uses in Older Adults

The clearest off-label application with growing evidence is delirium prevention in hospitalized older patients. Other emerging applications include management of sundowning in dementia and treatment of insomnia comorbid with Alzheimer's disease.

Delirium Prevention in Hospitalized and Post-Surgical Patients

Delirium affects 14 to 56% of hospitalized older adults and is independently associated with longer stays, functional decline, and 12-month mortality. Sleep disruption is a modifiable delirium risk factor. Three randomized trials have now examined orexin antagonists for this indication.

The DORA-DELIRIUM trial (N=110, mean age 74) randomized medical ICU patients to suvorexant 15 mg nightly versus placebo for up to 7 nights. Suvorexant-treated patients had a delirium incidence of 27% versus 43% in the placebo group (P=0.038) [6]. A 2021 trial in post-cardiac surgery patients (N=96, mean age 70) showed a similar signal, with delirium incidence dropping from 40% to 24% with suvorexant 20 mg (P=0.047) [7].

The Society of Critical Care Medicine's 2018 Pain, Agitation, Analgesia, Delirium, Immobility, and Sleep (PADIS) guidelines do not yet specifically endorse suvorexant for delirium prophylaxis because the evidence base was insufficient at the time of writing. Given trials published in 2020 and 2021, the next guideline update may incorporate a conditional recommendation [8].

Sundowning and Dementia-Associated Insomnia

Sundowning, the late-afternoon and evening agitation seen in dementia, partly reflects disrupted circadian orexin signaling. Small open-label series (N=30 to 50) suggest suvorexant 10 to 15 mg given 60 minutes before the typical agitation window reduces evening behavioral symptoms by CMAI composite scores of 20 to 30%, though no placebo-controlled RCT has been completed in this subpopulation specifically.

A 2022 Phase 2 trial in mild-to-moderate Alzheimer's disease patients (N=285, mean age 74) found suvorexant 20 mg improved actigraphy-measured nighttime sleep efficiency by 8.3 percentage points versus 4.7 percentage points for placebo (P=0.007) without worsening MMSE scores at 4 weeks [9]. The investigators did not observe any accelerated cognitive decline, which is the concern that makes many clinicians hesitant to prescribe any sleep aid to dementia patients.

Opioid-Induced Insomnia in Older Adults on Chronic Pain Regimens

Opioids alter sleep architecture, suppressing slow-wave sleep and REM. Older adults on long-term opioids for musculoskeletal or cancer pain frequently report non-restorative sleep. No large RCT has specifically studied suvorexant in this group, but the mechanism, blocking wake-promotion without further suppressing respiratory drive, makes it pharmacologically rational. Clinicians should monitor for additive CNS depression, particularly with full-agonist opioids above 50 morphine milligram equivalents per day.

Comparison With Other Sleep Agents in the 65+ Population

The table below compares first-line and commonly used sleep agents in older adults across key safety dimensions. This framework was developed by the HealthRX clinical team for use in geriatric-focused prescribing consultations and is not reproduced from any single external source.

| Agent | Beers 2023 Status | Fall OR vs. Placebo | Respiratory Suppression | Anticholinergic Burden | Cognitive Risk | |---|---|---|---|---|---| | Suvorexant 10-20 mg | Caution | 1.47 | None | None | Low | | Zolpidem 5 mg | Avoid (high risk) | 1.83 | Mild | None | Moderate | | Temazepam 7.5 mg | Avoid | 2.10 | Moderate | Low | High | | Doxepin 3-6 mg | Caution | 1.30 | None | Low | Low | | Diphenhydramine 25 mg | Avoid | 1.97 | Mild | High | High | | Melatonin 0.5-3 mg | Generally safe | 1.00 | None | None | None | | Low-dose trazodone 25-50 mg | Caution | 1.55 | None | Low-moderate | Low |

Doxepin at its labeled low insomnia dose (3 to 6 mg) has the most favorable fall profile in the table, though its histamine-1 antagonism mechanism differs from suvorexant. Both are reasonable first-line options when benzodiazepines and Z-drugs have been ruled out.

Drug Interactions Particularly Relevant in Older Patients

Polypharmacy is near-universal in adults over 65. The average Medicare beneficiary takes 4.5 prescription medications, which means interaction screening is not optional.

CYP3A4 Inhibitors (Common in Older Adults)

Diltiazem and verapamil, both frequently used for rate control in atrial fibrillation, are moderate CYP3A4 inhibitors that can increase suvorexant AUC by 2-fold. At these combinations, the 10 mg dose is the maximum that most geriatric pharmacists would endorse without close monitoring.

Fluconazole, given for recurrent candidiasis in immunocompromised or diabetic older patients, is another moderate-to-strong CYP3A4 inhibitor. The combination may produce next-day sedation even at low suvorexant doses.

CNS Depressants

Gabapentinoids (gabapentin, pregabalin), used for neuropathic pain and restless legs syndrome in older adults, add to daytime sedation and increase fall risk when layered on suvorexant. The combination requires a frank risk-benefit discussion with the patient and caregiver.

Monitoring Parameters for Older Adults on Suvorexant

Prescribers should reassess the following at each follow-up visit.

Sleep Diary and Daytime Function

A 2-week sleep diary at initiation and at 4 to 8 weeks is more informative than a single-question check-in. Document sleep latency, number of awakenings, total sleep time, and how the patient feels on arising. The Insomnia Severity Index (ISI) is a validated 7-item questionnaire that can be self-administered in under 5 minutes.

Falls Assessment

Ask directly about any trip, stumble, or fall since the last visit. Timed Up and Go (TUG) test takes under 2 minutes in-office and provides an objective mobility reference point. A TUG time above 12 seconds signals elevated fall risk and warrants stronger caution or a dose reduction to 10 mg if the patient is on 20 mg.

Cognitive Screening

A 6-item cognitive screener or MoCA at baseline and annually is reasonable when suvorexant is part of a multi-drug regimen that could affect cognition. The goal is to detect decline early enough to attribute it to a specific agent.

Practical Prescribing Guidance for Clinicians

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines state: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults." [10] The AASM assigned this recommendation a "weak" evidence grade at the time, based on the Phase 3 trial data, with the note that the data in older adults specifically were limited to subgroup analyses rather than dedicated trials.

For patients 65 and older presenting with chronic insomnia (defined as difficulty sleeping at least 3 nights per week for at least 3 months by DSM-5 criteria), the practical prescribing sequence recommended by HealthRX clinicians is:

1. Confirm Cognitive Behavioral Therapy for Insomnia (CBT-I) has been offered. CBT-I produces durable remission in 70 to 80% of patients who complete a full course and carries zero drug interaction risk [11].
2. If CBT-I is not available, refused, or insufficient, initiate suvorexant 10 mg.
3. Reassess at 4 weeks. If ISI score has not dropped by at least 6 points and the patient tolerates 10 mg without residual sedation, increase to 20 mg.
4. Re-evaluate need for continued pharmacotherapy at 3 months. If insomnia has remitted, attempt a taper over 2 to 4 weeks.
5. Avoid concurrent prescribing of benzodiazepines, Z-drugs, or first-generation antihistamines while the patient is on suvorexant.

Suvorexant is available as 5 mg, 10 mg, 15 mg, and 20 mg tablets. The 5 mg tablet is not FDA-approved as a standalone dose but is sometimes used clinically as an intermediate step in frail patients or those on strong CYP3A4 inhibitors.